share_log

EF Hutton Maintains Buy on UroGen Pharma, Maintains $25 Price Target

Benzinga ·  Nov 7 00:19  · Ratings

EF Hutton analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $25 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment